Rationale and design of the virological response and ribavirin dosage (VIRID) study in hepatitis.
Bergmann
J F
JF
Slavenburg
S
S
Roomer
R
R
de Knegt
R J
RJ
Drenth
J P H
JP
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009426:Netherlands; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin